Walleye Capital
SLNO

Walleye Capital’s Soleno Therapeutics SLNO Stock Holding History

Walleye Capital’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-17,000
Closed -$787K – 4948
2025
Q4 		$787K Buy
17,000
+14,400
+554% +$790K ﹤0.01% 2627
2025
Q3 		$176K Buy
+2,600
New +$193K ﹤0.01% 3403
2025
Q2 		– Sell
-110,000
Closed -$7.86M – 4995
2025
Q1 		$7.86M Buy
+110,000
New +$5.36M 0.04% 541

Other funds holding SLNO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return

Walleye Capital's SLNO Position: Q1 2026 in Review

Walleye Capital sold out of Soleno Therapeutics (SLNO) in Q1 2026, closing a stake of 16,983 shares — an estimated $786K sold.

Walleye Capital first reported a position in SLNO in Q3 2023 and held it in 6 quarters. The position peaked at $6.97M in Q1 2025. 225 funds tracked by Wall St. Rank hold SLNO as of Q1 2026.

  • Walleye Capital reported no remaining Soleno Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Walleye Capital sold 16,983 Soleno Therapeutics shares in Q1 2026, an estimated $786K.
  • Walleye Capital first reported a position in Soleno Therapeutics in Q3 2023 and held it in 6 quarters.
  • Walleye Capital's Soleno Therapeutics position peaked at $6.97M in Q1 2025.
  • 225 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.